Swedish-based pharmaceutical company Camurus has concluded the Phase II study of CAM2029 to treat acromegaly or neuroendocrine tumours (NETs).
Developed in collaboration with Novartis, CAM2029 is an octreotide subcutaneous product featuring FluidCrystal formulation that can be self applied by patients as a ready-to-use injection in a pre-filled syringe supported with a needle stick safety device.
It is intended to be used as an alternative to the existing, long-acting somatostatin analogue formulations.
The phase II trial is an open-label, multicentre, randomised study that involved 12 adult patients.
It was designed to evaluate the pharmacodynamics and pharmacokinetics profile, as well as the safety and efficacy of two dosing regimens of CAM2029.
Results have displayed therapeutic blood-levels of octreotide over four weeks.
The trial has also demonstrated a consistent safety and local tolerability of CAM2029 across the study.
Camurus president and CEO Fredrik Tiberg said: "The positive pharmacokinetic profile and promising disease control data seen in this Phase II study when switching patients from Sandostatin LAR to CAM2029, together with the option for self-administration by patients, underscores the potential for CAM2029 to fill an unmet medical need."
The company is currently preparing for a Phase III clinical trial of CAM2029 in association with Novartis and is expected to start next year.